Sarcopenia
Conditions
Interventions
Treatment group:Treatment with Jin-Tian-Ge capsule
Control group:Treatment with the simulant of Jin-Tian-Ge capsule, which is composed of starch+caramel
Sponsors
Xi’an Honghui Hospital
Eligibility
Sex/Gender
All
Age
50 Years to 100 Years
Inclusion criteria
Inclusion criteria: (1) Diagnosed with sarcopenia according to "Asian Working Group for Sarcopenia: 2019 Consensus Update on Sarcopenia Diagnosis and Treatment". (2) Age =50 years old, gender is not limited. (3) Voluntarily subjected to the test and signed an informed consent form. (4) BMD > -2.5 SD in lumbar vertebrae (L1-L4) and hip.
Exclusion criteria
Exclusion criteria: (1) Major diseases that may affect the results of the present study: ? Rheumatic immune system diseases: rheumatoid arthritis, systemic lupus erythematosus; ? Endocrine system diseases: hyper/hypothyroidism, diabetes mellitus; ? Severe cardiovascular system diseases: hypertension grade 2 or above, myocardial infarction, congenital heart disease, cardiac insufficiency, after cardiac surgery; ? Neurological system diseases: myasthenia gravis, periodic paralysis, polymyositis, dermatomyositis, Parkinson's syndrome and stroke and other causes of paralysis; ? Hematological system diseases: immune thrombocytopenia (platelets <90X10E9/L), moderately severe anemia (HGB <90g/L); ? Combined respiratory, gastrointestinal, urinary and other major system diseases; (vii) Serious liver and kidney function serious abnormalities caused by various reasons, AST/ALT greater than 1.5 times the upper limit of normal value; ? Serious infectious diseases of various organs; ? Combined with diseases that affect BMD and calcium and phosphorus metabolism; ? Various malignant tumors; (2) The use of traditional Chinese medicine in the past month and the use of drugs affecting bone and muscle metabolism in the past six months (bisphosphonates, estrogens, calcitonin, vitamin D, teriparatide, disulfiram, etc.); (3) Previous history of allergy to proprietary Chinese medicines; (4) Patients who are illiterate, suffering from mental illness, dementia who cannot cooperate to complete the clinical study; (5) Patients who are too obese to undergo bone mineral density examination and body composition analysis; (6) Participating in other clinical studies at the same time.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Skeletal muscle mass index;Muscle strength (grip strength);Somatic function (testing 6m step speed, 5 sit-up test, SPPB score);ADL Rating Scale for Activities of Daily Living, SARC-CalF Scale; | — |
Secondary
| Measure | Time frame |
|---|---|
| Serum biochemical indicators (ALP?25OHD?PTH?CTX?P1NP?Ga?Pi?CK?CKMB);Fall risk;bone mineral density;Anthropometric indicators: height, weight, waist, hip, calf circumference; | — |
Countries
China
Contacts
Public ContactYuhong Zeng
Xi’an Honghui Hospital
Outcome results
None listed